Literature DB >> 28138202

Treating an Adolescent with Long QT Syndrome for Bipolar Disorder: A Case Presentation.

Özlem Önen1, Ayşe Kutlu1, Handan Özek Erkuran1.   

Abstract

OBJECTIVES: Long QT syndrome (LQTS) is described as the development of sudden syncope attacks or death as a result of ventricular tachycardia (VT) episodes that might be observed as elongated QT interval in electrocardiography (ECG). Implantable Cardioverter Defibrillator (ICD) is recommended as first-line treatment for the condition in guidelines. We aimed to present an adolescent recently diagnosed with Bipolar Disorder (BD) who had LQTS that was treated with ICD, discussing her follow up and treatment along with relevant literature.
METHODS: Psychiatric assessment of the case that applied to our child psychiatry unit due to manic symptoms were carried out by using Diagnostic and Statistical Manual of Mental Disorders 5th edition (DSM-5) criteria. Symptom severity was monitored via Young Mania Rating Scale scores (YMRSS).
RESULTS: The case met criteria for Bipolar Disorder Type I (BD-I). She had improvement in her mood symptoms with treatment regimen as risperidone 3 mg/day, valproate 1000 mg/day and lorazepam 1 mg/dayi after her 2-week follow up as well as no reported ICD activity, reflecting fine cardiac functions and rhythm.
CONCLUSIONS: LQTS is a serious health issue for children and adolescents diagnosed with BD. This condition should be kept in mind especially in cases where familial risk factors are present and precautions need to be maintained upon required assessments. These cases need to be closely monitored due to risk factors related to both BD and LQTS, in a multidisciplinary fashion, involving both psychiatry and cardiology divisions.

Entities:  

Keywords:  arrhythmia; bipolar disorder; long QT syndrome; psychotropic medication

Mesh:

Substances:

Year:  2017        PMID: 28138202      PMCID: PMC5274529     

Source DB:  PubMed          Journal:  Psychopharmacol Bull        ISSN: 0048-5764


  21 in total

Review 1.  Long QT syndrome.

Authors:  G M Vincent
Journal:  Cardiol Clin       Date:  2000-05       Impact factor: 2.213

Review 2.  Congenital and acquired long QT syndrome.

Authors:  A J Camm; M J Janse; D M Roden; M R Rosen; J Cinca; S M Cobbe
Journal:  Eur Heart J       Date:  2000-08       Impact factor: 29.983

3.  Sudden death in patients receiving clozapine treatment: a preliminary investigation.

Authors:  I Modai; S Hirschmann; A Rava; R Kurs; P Barak; P Lichtenberg; M Ritsner
Journal:  J Clin Psychopharmacol       Date:  2000-06       Impact factor: 3.153

Review 4.  Multiple mechanisms in the long-QT syndrome. Current knowledge, gaps, and future directions. The SADS Foundation Task Force on LQTS.

Authors:  D M Roden; R Lazzara; M Rosen; P J Schwartz; J Towbin; G M Vincent
Journal:  Circulation       Date:  1996-10-15       Impact factor: 29.690

5.  Thioridazine (Mellaril) and mesoridazine (Serentil): prolongation of the QTc interval.

Authors:  S Dallaire
Journal:  CMAJ       Date:  2001-01-09       Impact factor: 8.262

6.  Implantable cardioverter defibrillator therapy for prevention of sudden cardiac death in children in the Netherlands.

Authors:  Jogien H M Heersche; Nico A Blom; Freek van de Heuvel; Christiaan Blank; Annette G Reimer; Sally-Ann Clur; Maarten Witsenburg; A Derk Jan ten Harkel
Journal:  Pacing Clin Electrophysiol       Date:  2009-12-15       Impact factor: 1.976

7.  Spectrum of mutations in long-QT syndrome genes. KVLQT1, HERG, SCN5A, KCNE1, and KCNE2.

Authors:  I Splawski; J Shen; K W Timothy; M H Lehmann; S Priori; J L Robinson; A J Moss; P J Schwartz; J A Towbin; G M Vincent; M T Keating
Journal:  Circulation       Date:  2000-09-05       Impact factor: 29.690

Review 8.  The long QT syndrome and torsade de pointes.

Authors:  N el-Sherif; G Turitto
Journal:  Pacing Clin Electrophysiol       Date:  1999-01       Impact factor: 1.976

Review 9.  Antipsychotic-related QTc prolongation, torsade de pointes and sudden death.

Authors:  Peter M Haddad; Ian M Anderson
Journal:  Drugs       Date:  2002       Impact factor: 9.546

10.  New Generation Antipsychotic Drugs and QTc Interval Prolongation.

Authors:  W VictorR Vieweg
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2003-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.